Cargando…
Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
Introduction: Hyperprogressive disease (HPD) is a state of accelerated tumor growth from cancer immunotherapy, associated with poor outcome. The reported incidence is 6% to 29% among studies using varying definitions of HPD, with no predictive biomarkers. Tumor infiltrating lymphocytes (TILs) are pr...
Autores principales: | Kanjanapan, Yada, Guduguntla, Geetha, Varikara, Ashwati Krishnan, Szajer, Jeremy, Yip, Desmond, Cockburn, John, Fadia, Mitali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612441/ https://www.ncbi.nlm.nih.gov/pubmed/37885403 http://dx.doi.org/10.1177/15330338231209129 |
Ejemplares similares
-
Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
por: Kanjanapan, Yada, et al.
Publicado: (2020) -
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020) -
Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
por: Long, Yaping, et al.
Publicado: (2023) -
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019) -
Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)